Shionogi & Co. Ltd. has synthesized spiroheterocycle derivatives acting as 5-HT2A and 5-HT2C receptor antagonists and/or inverse agonists reported to be useful for the treatment of neurodegeneration.

Delix Therapeutics recently published findings from a study about the mechanism that causes psychoplastogens and serotonin to activate the 5-HT2A receptor in different ways. The paper, developed in ...

Once synonymous with hippies and hallucinatory experiences, psychedelic drugs are now being explored for their medical potential.

Signals in our brain are not always processed in the same way: Certain receptors modulate these mechanisms, influencing our mood, perception, and behavior in various ways. One of these is the 5-HT2A ...

Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest research, Treatment with shRNA to ...

Receptors mediate the transmission of information between nerve cells. The release of serotonin alters nerve cell activities throughout the brain. At least 14 types of serotonergic receptors can be ...

This article was originally published on Psychedelic Spotlight and appears here with permission. New study suggests that a non-hallucinogenic LSD analog may hold therapeutic potential for mood ...

It is becoming increasingly accepted that classic psychedelics like LSD, psilocybin, ayahuasca, and mescaline can act as antidepressants and anti-anxiety treatments in addition to causing ...

SEATTLE--(BUSINESS WIRE)--Küleon LLC, a preclinical-stage biotechnology company building a best-in-class library of selective, G-protein-biased serotonergic medicines, today announced it has been ...